PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins,

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to present 3 oral presentations and 12 posters at AAN 2026Visit Praxis at Booth #2324 for an in-booth speaker showcase featuring Phase 3 Essential3 results for ulixacaltamide,

Eli Lilly's Jaypirca builds case with fourth positive phase 3 trial in blood cancer patients

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), which showed significant improvement in progression-free survival when combined with venetoclax and rituximab.

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety
Fierce Biotech

Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its phase 3 program.
Medscape

TYK2 Inhibitor Promising for Moderate-to-Severe Psoriasis in Phase 3 Studies

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety concerns emerging.
Managed Healthcare Executive

Phase 3 trial program begins for investigational sleep medication, alixorexton

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy of alixorexton compared with placebo in adults, according to a news release. Alixorexton is an investigational treatment for narcolepsy types 1 and 2 and idiopathic hypersomnia (IH).
FierceBiotech

Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in November, the British biotech sounded confident that the latest readout set them up for a phase 3 trial. But by the sound of Silence ...

Diamyd Medical AB (publ) (DYMDF) Discusses Negative Interim Results From Phase 3 DIAGNODE-3 Trial Transcript

Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will now discuss what this means with Ulf Hannelius,

Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices?

In recent days, Ocular Therapeutix highlighted upcoming presentations by its senior scientific and clinical leaders at major ophthalmology meetings, where they discussed evolving treatment approaches for neovascular age-related macular degeneration and diabetic retinal disease.